Physician profile
John Deberry
NPI 1457314197
$3,849.83
in general payments reported to CMS, 2019-2025
23 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $187 · 2021: $274 · 2022: $332 · 2023: $414 · 2024: $1,094 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.50 |
| Education | $123.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,594.90 | 2019-2025 | Erleada, Akeega, Carvykti |
| Pfizer INC. | $596.28 | 2019-2025 | |
| Astellas Pharma US INC | $537.55 | 2019-2025 | Xtandi |
| Sumitomo Pharma America, INC. | $219.87 | 2023-2025 | Gemtesa, Orgovyx |
| Teleflex LLC | $109.05 | 2022-2025 | Urolift, Barrigel |
| Coloplast Corp | $80.41 | 2019-2020 | |
| Myovant Sciences INC. | $69.21 | 2021-2022 | |
| Urogen Pharma, INC. | $68.63 | 2024 | |
| Axonics, INC. | $65.84 | 2020-2024 | Axonics |
| Valencia Technologies Corporation | $60.84 | 2025 | Ecoin Device Kit |
| Abbvie INC. | $54.34 | 2021-2025 | |
| Urovant Sciences INC | $49.37 | 2021-2022 | |
| Astellas Pharma Global Development | $49.34 | 2025 | Xtandi |
| Verity Pharmaceuticals INC. | $39.21 | 2021 | |
| Telix Pharmaceuticals | $37.75 | 2023 | Illuccix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mckesson Patient Care Solutions INC. | $36.70 | 2019 | |
| Boston Scientific Corporation | $36.25 | 2025 | General - Female Sui, General - Erectile Dysfunction |
| Medtronic, INC. | $34.37 | 2025 | Altaviva, Interstim |
| Ferring Pharmaceuticals INC. | $33.66 | 2019 | |
| Olympus America INC. | $25.69 | 2024 | Itind System |
| Accord Healthcare, INC. | $18.28 | 2022 | |
| Tempus Ai, INC | $17.51 | 2024 | |
| C. R. Bard, INC. & Subsidiaries | $14.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Deberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.